BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34695519)

  • 1. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis.
    Chow R; Murdy K; Vaska M; Lee SL
    Radiother Oncol; 2021 Dec; 165():37-43. PubMed ID: 34695519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study.
    Kamarajah SK; Phillips AW; Hanna GB; Low D; Markar SR
    Ann Surg; 2022 Mar; 275(3):526-533. PubMed ID: 32865948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment to "Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis".
    Kao YS; Chen YF
    Radiother Oncol; 2022 Apr; 169():163. PubMed ID: 35065147
    [No Abstract]   [Full Text] [Related]  

  • 4. Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma.
    Ogawa K; Ishikawa H; Hisakura K; Hiroshima Y; Moriwaki T; Yamada T; Yamamoto Y; Akashi Y; Owada Y; Ohara Y; Enomoto T; Furuya K; Doi M; Shimomura O; Takahashi K; Hashimoto S; Sakurai H; Oda T
    Int J Clin Oncol; 2021 Oct; 26(10):1856-1863. PubMed ID: 34241725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter to the editor regarding the article "Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis" by Chow et al.
    Zhu J; Tan Y; Wang Q
    Radiother Oncol; 2022 Apr; 169():152-153. PubMed ID: 35131341
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival Comparison Among Neoadjuvant Chemoradiotherapy Followed by Esophagectomy, Definitive Chemoradiotherapy, and Esophagectomy Alone for Esophageal Squamous Cell Carcinoma.
    Chen HS; Lin CH; Wu SC; Wang BY
    Ann Surg Oncol; 2022 Jun; 29(6):3617-3627. PubMed ID: 34994899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
    Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chang YL; Cheng YF; Chen HS; Wu SC; Hung WH; Chen HC; Huang CL; Cheng CY; Wang BY
    PLoS One; 2022; 17(10):e0271338. PubMed ID: 36227954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.
    Klevebro F; Nilsson K; Lindblad M; Ekman S; Johansson J; Lundell L; Ndegwa N; Hedberg J; Nilsson M
    Dis Esophagus; 2020 May; 33(5):. PubMed ID: 31676895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophagectomy versus definitive chemoradiotherapy as initial treatment for clinical stage I esophageal cancer: a systematic review and meta-analysis.
    Mei LX; Mo JX; Chen Y; Dai L; Wang YY; Chen MW
    Dis Esophagus; 2022 Mar; 35(3):. PubMed ID: 34318324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
    Sjoquist KM; Burmeister BH; Smithers BM; Zalcberg JR; Simes RJ; Barbour A; Gebski V;
    Lancet Oncol; 2011 Jul; 12(7):681-92. PubMed ID: 21684205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature.
    Voeten DM; den Bakker CM; Heineman DJ; Ket JCF; Daams F; van der Peet DL
    World J Surg; 2019 May; 43(5):1271-1285. PubMed ID: 30607604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
    Chen CY; Li CC; Chien CR
    World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
    Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
    PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
    Lin G; Han SY; Xu YP; Mao WM
    Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia.
    Kuo YH; Chien YW; Chen PR; Feng CL; Li CC; Chien CR
    World J Surg Oncol; 2019 Dec; 17(1):222. PubMed ID: 31856840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.